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Metformin, but Not Rosiglitazone,
Attenuates the Increasing Plasma
Levels of a New Cardiovascular
Marker, Fibulin-1, in PatientsWith
Type 2 Diabetes
OBJECTIVE
The extracellular matrix protein ﬁbulin-1 is upregulated in the arterial wall in
type 2 diabetes (T2D) and circulates in increased concentrations in diabetes.
Metformin is an antidiabetic drug with beneﬁcial cardiovascular disease effects in
diabetes. We hypothesized that metformin would inﬂuence the increased level of
plasma ﬁbulin-1 in diabetes.
RESEARCH DESIGN AND METHODS
After a 4-week run-in period, 371 eligible patients with T2D were randomized to
treatment groups in a factorial design including insulin alone (control), +metfor-
min, +rosiglitazone, or +both metformin and rosiglitazone. Plasma ﬁbulin-1 was
analyzed at the beginning of the study and after 18 and 24 months.
RESULTS
Plasma ﬁbulin-1 increased in all groups throughout the 2-year period; however,
the increase was strongly attenuated among patients treated with metformin.
A highly signiﬁcant difference was observed when the mean change in plasma
ﬁbulin-1 was compared between metformin- and non–metformin-treated indi-
viduals both at 18 and 24 months of treatment, but rosiglitazone had no effect.
Metformin and rosiglitazone alone reduced the HbA1c levels to comparable levels
and in combination even further.
CONCLUSIONS
Metformin attenuates the increase in plasma ﬁbulin-1 concentrations in T2D,
independently of glycemic effects. Changes in ﬁbulin-1 may reﬂect an important
element in diabetic arteriopathy that can be inﬂuenced by metformin.
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Increased mortality and morbidity owing to a higher incidence of cardiovascular
diseases (CVDs) is a major clinical challenge in type 2 diabetes (T2D) (1,2). Several
studies have demonstrated that management of hypertension, LDL cholesterol, and
other major CVD risk factors have reduced micro- and macrovascular complications
in patients with T2D; however, optimal risk reduction is still not achieved when
these important risk factors are controlled, indicating that further attempts are
needed to control the CVD risk burden (3–5). One assumption is that improvement
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of the glycemic status will reduce risk;
however, whether this is correct, and if
different antidiabetic drugs perform
differently, is still not clear. One
obstacle for the judgment of treatment
efﬁcacies has been the lack of useful
markers for the improvement of speciﬁc
elements in the arterial damage induced
by diabetes.
In the UK Prospective Diabetes Study
(UKPDS), it has been shown that
metformin signiﬁcantly reduces
macrovascular events in T2D (6) and,
impressively, that this effect is sustained
for 10 years (7). This result is assumed to
be related to metformin’s well-known
ability to reduce plasma glucose due to
increased insulin-stimulated glucose
uptake in peripheral tissue, decreased
glycogenolysis, and suppressed hepatic
gluconeogenesis (8). However, it has
also been suggested that the effect of
metformin is at least partly independent
of its blood glucose–lowering effect (9).
This idea is compatible with a recent
study that found beneﬁcial effects on
cardiovascular outcome in T2D patients
with coronary artery disease on
metformin compared with glipizide,
despite similar effects on HbA1c (10).
The mechanisms by which metformin
exerts such putative beneﬁcial
cardiovascular effects are unclear but
have been suggested to include an
ability to reduce inﬂammatory and
coagulative activities and to reduce the
expression of vascular adhesion
molecules as well as improve
endothelial function and ﬁbrinolysis
(11–15). These explanations are mainly
based on data from experimental animal
and in vitro studies. A few results from
human studies have, however, indicated
that there is an effect of metformin
treatment on endothelial markers and
this effect may be independent of the
effects on the glycemic status (16).




matrix [ECM] modiﬁcations and
accumulations, and calciﬁcations) as
well as increased occurrence of
atherosclerotic plaques. We have
recently identiﬁed the ECM gene
product, ﬁbulin-1 mRNA, as the
most upregulated transcript in
nonatherosclerotic arterial tissue from
patients with T2D (17). In the initial
presentation, we found higher amounts
of ﬁbulin-1 protein both in the arterial
wall and in the circulation among
patients with T2D. Moreover, we
demonstrated an association between
increased levels of plasma ﬁbulin-1 and
arterial stiffness, blood pressure, and
glycemic status in a cohort of 305 well-
described patients with T2D (18). These
results, concerning relations between
plasma ﬁbulin-1, glycemic status, and
hypertension, have been conﬁrmed in
three subsequent studies (19–21). In
the initial paper, we also presented a
15-year follow-up study, showing that
high plasma ﬁbulin-1 concentrations
among patients with T2D were
independently predictive of mortality in
T2D with a hazard ratio similar to that of
plasma cholesterol (18). In the initially
investigated diabetic patients, we
observed that individuals treated with
metformin had reduced ﬁbulin-1 levels
(18). Taken together, our previous
results suggested that ﬁbulin-1 is
involved in arterial disease in T2D, and
that the circulating concentration may
serve as a biomarker for vascular ECM
changes as part of diabetic arteriopathy.
Fibulin-1 is a member of the ﬁbulin
family (22) and was identiﬁed by
Argraves et al. (23) in 1989. It is an
ECM glycoprotein found in high
concentrations in blood vessels, lungs,
and skin in association with elastic
ﬁbers, ﬁbronectin microﬁbrils, and
some basement membranes. Fibulin-1
is additionally present in high
concentrations in plasma (24). Fibulin-1
knockout mice die early in utero with
signs of endothelial and cardiovascular
malformations (25,26); however, its
exact molecular role is not known.
In the current study, we hypothesized
that the vasculoprotective actions of
metformin could include changes in the
arterial cells and their surroundings,
which may be reﬂected by alterations in
the concentration of the new diabetes
marker, ﬁbulin-1. We therefore
investigated plasma ﬁbulin-1
concentrations in a previously published
randomized trial, where a factorial
design was used to explore effects of
randomized treatments with metformin
and rosiglitazone.
RESEARCH DESIGN AND METHODS
Subjects
Patients between 30 and 70 years of age
with T2D were admitted to eight
hospital centers participating in the
South Danish Diabetes Study (SDDS)
conducted between January 2003 and
July 2006 (27). Eligibility criteria
included BMI.25 kg/m2, fasting plasma
C-peptide.300 pmol/L, HbA1c.7% (53
mmol/mol), diagnosis of T2D at least
2 years before participation, and
treatment for at least 3 months with
stable doses of oral antidiabetics and/
or insulin. Exclusion criteria included
impaired renal function, congestive
heart failure, and known intolerance to
metformin or rosiglitazone. The study
was approved by the regional
committee on biomedical research
ethics (M-2417-02) and performed in
accordance with the Declaration of
Helsinki. All subjects provided written
informed consent.
Study Design and Setting
The study is a prospective, randomized,
and partly placebo-controlled trial with
450 patients included. After a 4-week
run-in period, 371 eligible patients were
randomized to one of eight treatment
groups in a factorial design with NPH
insulin versus insulin aspart, metformin
versus placebo, or rosiglitazone versus
placebo, as previously described (27).
The factorial design made it possible, in
the present paper, to present the
combined results from groups treated
with the two different insulins, since
these treatment modalities did not
inﬂuence plasma ﬁbulin-1.
Consequently, the results from four
groups (presented in Table 1) are
therefore reported as insulin alone (i.e.,
subjects only treated with insulin),
+rosiglitazone (i.e., subjects treated
with insulin and rosiglitazone),
+metformin (i.e., individuals treated
with insulin and metformin), and +Rosi
+Met (i.e., subjects treated with insulin
and both rosiglitazone andmetformin in
combination).
Intervention
Metformin or placebo was administered
as one 500-mg tablet twice a day during
the ﬁrst 4 weeks succeeded by two
tablets twice daily. Rosiglitazone or
placebo was given as one 4-mg tablet
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per day for the ﬁrst 4 weeks succeeded
by one tablet twice a day.
Clinical and Biochemical
Measurements
Blood was drawn for HbA1c and plasma
measurements at baseline and after 1
and 2 years. HbA1c was measured every
3 months by cation exchange
chromatography using Tosoh G7
(Medinor, Broendby, Denmark). Total
cholesterol, LDL, HDL, and triglycerides
were measured on a Modular Analytics
P instrument (Roche Diagnostics, Basel,
Switzerland) according to the
manufacturer’s instructions. Plasma
ﬁbulin-1 was measured with a sandwich
immunoassay as previously described
(18). The plasma concentration of
metformin was determined by a
validated high-performance liquid
chromatography method (28). The limit
of quantiﬁcation for metformin in
plasma was found to be 10 ng/mL. The
limit of detection for metformin in
plasma was found to be 5 ng/mL. The
intra- and interday precision did not
exceed 7.5% for plasma.
Statistical Analysis
Analyses were performed using SPSS
20.0 (SPSS Inc., Chicago, IL), and
GraphPad Prism 5 (GraphPad Software,
La Jolla, CA) was applied to draw ﬁgures.
Data from the groups of subjects
receiving either insulin alone (control),
metformin, rosiglitazone, or a
combination of metformin and
rosiglitazone were ﬁrst analyzed by one-
way ANOVA and then with unpaired
Student t test. Bivariate linear
correlations were calculated by
determining the Pearson correlation
coefﬁcient. P , 0.05 was considered
signiﬁcant in all analyses. Data are
presented as untransformed means 6
SEM.
RESULTS
The HbA1c results for all eight treatment
groups have previously been reported
(27). In Table 1, we present baseline
patient characteristics for the four
treatment groups, which are the main
focus in this investigation, i.e., patients
treated with insulin only (NPH or aspart,
control), metformin only, rosiglitazone
only, or a combination ofmetformin and
rosiglitazone. We focus on these four
groups and the effect of treatment with
either NPH or aspart insulin is not
considered, since we observed no
differences between these two insulin
treatment modalities in relation to
plasma ﬁbulin-1 and since no
interference in the presented data
occurred when insulin treatment was
included (data not shown). There were
no differences at baseline in clinical
parameters between the four groups, as
presented in Table 1. The percentage of
patients receiving medications other
than antidiabetics is reported in Table 2.
There were no statistical differences
between drug use in the four groups and
no inﬂuence of any drug on plasma
ﬁbulin-1 concentration. No differences
in any groups were observed when
considering delta mean values (the
difference between baseline and 2
years) of LDL, triglycerides, and free
Table 1—Baseline values of the four study groups
Insulin alone +Rosiglitazone +Metformin +Rosi+Met
BMI (kg/m2) 34 6 0.6 33 6 0.5 35 6 0.7 34 6 0.6
Body weight (kg) 100 6 1.9 98 6 1.6 103 6 1.9 100 6 1.8
Sex (female/male) 38/56 38/55 36/54 30/64
Age (years) 56 6 0.8 57 6 0.9 56 6 0.9 56 6 0.9
Diabetes duration (years) 8.5 6 0.5 9.5 6 0.7 8.6 6 0.4 8.8 6 0.6
HbA1c (%) (mmol/mol) 8.6 6 0.1 (70 6 1.2) 8.6 6 0.1 (70 6 1.3) 8.6 6 0.1 (70 6 1.5) 8.7 6 0.1 (72 6 1.4)
Systolic blood pressure (mmHg) 145 6 1.6 147 6 2 145 6 2 145 6 2
Diastolic blood pressure (mmHg) 83 6 0.9 85 6 0.9 85 6 1.1 84 6 1
Pulse pressure (mmHg) 61 6 1.4 62 6 1.6 60 6 1.5 60 6 1.6
HDL (mmol/L) 1.3 6 0.03 1.3 6 0.05 1.3 6 0.04 1.2 6 0.03
LDL (mmol/L) 2.8 6 0.1 2.8 6 0.09 3 6 0.1 2.7 6 0.09
Total cholesterol (mmol/L) 5 6 0.1 4.9 6 0.1 5.2 6 0.1 4.7 6 0.1
Plasma triglycerides (mmol/L) 2.2 6 0.1 2.2 6 0.2 2.6 6 0.3 2.1 6 0.1
Plasma FFA (mmol/L) 0.58 6 0.03 0.52 6 0.03 0.54 6 0.02 0.55 6 0.03
Plasma ﬁbulin-1 (mg/mL) 46 6 1.3 47 6 1.3 47 6 1.3 45 6 1.2
There were no signiﬁcant differences between the insulin alone group and any treatment groups. Data are presented asmeans6 SEM. Student t test
for nonpaired data was used.
Table 2—Percentage of patients treated with different medications
Insulin alone +Rosiglitazone +Metformin +Rosi+Met
Antihypertensives (RAAS-related)
Angiotensin inhibitors 67 74 70 68
ACE inhibitors 51 58 64 53
Angiotensin II R inhibitors 30 34 26 23
Other antihypertensives
CA antagonists 23 18 36 29
Diuretics 62 55 69 59
b-Blockers 23 25 23 22
Statins 70 68 68 70
Acetylsalicylic acids 44 37 33 46
RAAS, renin-angiotensin-aldosterone system.
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fatty acid (FFA) (Table 3). HDL
cholesterol increased in both groups
receiving rosiglitazone (Table 3). No
differences were observed in delta
mean values of systolic and diastolic
blood pressures, as well as pulse
pressures. BMI and body weight were
signiﬁcantly increased in the
rosiglitazone group compared with the
control group (Table 3). Weight gain was
reduced in the patients receiving the
combined therapy compared with those
receiving rosiglitazone alone (Table 3).
The mean delta values of HbA1c were
signiﬁcantly lowered in both the
rosiglitazone alone and the metformin
alone groups (;0.5%) and further
reduced in the rosiglitazone and
metformin combination group (;1%)
(Table 3 and Fig. 1B).
There were no statistically signiﬁcant
differences in plasma ﬁbulin-1 among
the four groups at baseline. The
concentration of ﬁbulin-1 correlated
weakly but signiﬁcantly or borderline
signiﬁcantly to age, HbA1c, and pulse
pressure at baseline in the entire
population (age: r = 0.22, P , 0.001;
HbA1c: r = 0.10, P = 0.080; pulse
pressure: r = 0.14, P = 0.006). As can be
seen in Fig. 1A, the plasma
concentration of ﬁbulin-1 increased
signiﬁcantly in the control group after 1
and 2 years and in the group treated
with rosiglitazone only. In contrast, the
plasma ﬁbulin-1 concentration did not
change with time in the two groups
receiving metformin either alone or in
combination with rosiglitazone. This
difference resulted in signiﬁcantly lower
plasma ﬁbulin-1 concentrations after 2
years in the two metformin-treated
groups compared with the two groups
not treated with metformin (Fig. 1A).
There was no correlation between delta
values of plasma ﬁbulin-1 and delta
values of HbA1c in any treatment
groups. Likewise, no correlations were
observed between delta values of
plasma ﬁbulin-1 and baseline
characteristics or delta values of lipid or
blood pressure values.
Bivariate correlation analysis
demonstrated a signiﬁcant negative
relationship between delta values of
plasma ﬁbulin-1 (2-year value minus
baseline value) and the mean trough
steady-state plasma concentration of
all metformin-treated patients at the
1-year time point (r =20.26, P = 0.001),
i.e., high metformin concentration was
associated with a low increase or even a
decrease in plasma ﬁbulin-1.
CONCLUSIONS
In this 2-year, investigator-driven,
prospective, randomized, partly blinded
trial (27), we tested the hypothesis that
metformin and/or rosiglitazone
modulates the level of plasma ﬁbulin-1
in patients with T2D. We found a
signiﬁcant ﬁbulin-1–lowering effect of
metformin, but not of rosiglitazone. This
ﬁnding is in accordance with results
from a previous observational study
where we observed lower plasma
ﬁbulin-1 concentrations among
metformin-treated T2D patients (18).
We ﬁnd that the metformin-induced
effect on plasma ﬁbulin-1 is probably
not mediated by improved glycemic
status, since no effect on ﬁbulin-1 was
observed after rosiglitazone treatment
even though HbA1c was reduced to the
same level in the metformin-only group,
and no additional effect on plasma
ﬁbulin-1 was observed when HbA1c was
further reduced by rosiglitazone and
metformin combination treatment. In
addition, no association between delta
HbA1c and delta ﬁbulin-1 values was
observed. Further strengthening the
direct connection between metformin
treatment and ﬁbulin-1, we observed an
association between the change in
plasma ﬁbulin-1 level and the circulating
concentration of metformin.
Using a hypothesis-free gene expression
microarray experiment, we recently
identiﬁed ﬁbulin-1 as the most
upregulated mRNA transcript in
nonatherosclerotic arterial tissue from
patients with T2D (17). The ﬁbulin-1
protein amounts were also higher in
arterial tissue from patients with T2D.
These results are in agreement with
previous ﬁndings of arterial ECM
modulations in T2D (18). Fibulin-1 is also
present at high levels in plasma, and in
our previous study, we also found higher
circulating amounts of ﬁbulin-1 in
patients with T2D. Moreover, the level
of plasma ﬁbulin-1 correlates with the
glycemic status as well as blood
Table 3—Mean delta values of clinical parameters from baseline to 2 years
Insulin alone +Rosiglitazone +Metformin +Rosi+Met
BMI (kg/m2) 1.89 6 0.3 3.05 6 0.4* 1.51 6 0.3† 2.2 6 0.4
Body weight (kg) 5.73 6 0.8 9.27 6 0.9** 4.42 6 0.6†† 5.77 6 0.9§§
HbA1c (%) 20.56 6 0.12 21.26 6 0.19** 21.31 6 0.15*** 21.83 6 0.17***§
HbA1c (mmol/mol) 26.1 6 1.4 213.8 6 2.0** 214.3 6 1.7*** 220 6 1.8***§
Systolic blood pressure (mmHg) 25.45 6 2.4 29.97 6 1.7 25.44 6 2.2 29.44 6 2.3
Diastolic blood pressure (mmHg) 25.35 6 1.3 25.69 6 1.2 26.99 6 1.7 26.69 6 1.3
Pulse pressure (mmHg) 20.61 6 2.8 24.83 6 2 26.69 6 1.3 24.25 6 2.7
HDL (mmol/L) 0.09 6 0.02 0.21 6 0.07* 0.06 6 0.04 0.25 6 0.03***¶¶
LDL (mmol/L) 20.6 6 0.1 20.31 6 0.1 20.73 6 0.1 20.47 6 0.1
Total cholesterol (mmol/L) 20.52 6 1.23 20.11 6 0.14* 20.7 6 0.12† 20.31 6 0.12¶
Plasma triglycerides (mmol/L) 20.18 6 0.13 20.35 6 0.14 20.55 6 0.28 20.4 6 0.12
Plasma FFA (mmol/L) 20.08 6 0.04 0.07 6 0.09 20.03 6 0.03 20.07 6 0.03
Plasma ﬁbulin-1 (mg/mL) 7.32 6 1.2 5.71 6 1 1.28 6 1.15***† 0.96 6 0.93***§§§
Data are mean values at the ﬁrst visit subtracted frommeans at the last visit. Data are presented as means6 SEM. Student t test for nonpaired data
was used. ***P, 0.001. **P, 0.01. *P, 0.05 for insulin alone vs. treatment. ††P, 0.001. †P, 0.01 for rosiglitazone vs. metformin. §§§P, 0.001.
§§P , 0.01. §P , 0.05 for rosiglitazone vs. +Rosi+Met. ¶¶P , 0.001. ¶P , 0.05 for metformin vs. +Rosi+Met.
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pressure and carotid compliance, but
not with lipids and CRP. In addition,
plasma ﬁbulin-1 concentrations
independently predicted mortality in a
15-year follow-up period (18). Thus,
plasma ﬁbulin-1 appears as a new
biomarker for vascular damage, which is
in line with the results from four
subsequent studies, where plasma
ﬁbulin-1 was found to be associated
with diabetes, hypertension, and kidney
damage (19–21). Interestingly, two of
these studies used non–hypothesis-
driven proteomic approaches to search
for new markers (20,21). In the current
study, we could conﬁrm the previously
observed associations between plasma
ﬁbulin-1 and age, glycemic status, and
pulse pressure, although the
correlations were not as strong as
previously reported (18). Our current
observation of increasing levels of
plasma ﬁbulin-1 during the 2-year study
period may partly be explained, since
we previously observed an association
with age; however, the increase is rather
large, and whether this is related to the
effects of factors related to the diabetic
condition is not known. We did not
observe correlations to systolic blood
pressure as previously seen (18);
nevertheless, in our previous study,
blood pressure measurements were
obtained stringently after a period of
rest, whereas in the current study, blood
pressure measurements were not
obtained as rigorously (18).
Metformin is recommended as the drug
of choice in the treatment of T2D (29)
and has been shown to provide a
protective effect on the cardiovascular
system (6,7,15,30,31), although its exact
protective mechanism is not clariﬁed. In
the UKPDS, metformin treatment in
obese patients with T2D has been
shown to reduce the incidence of
cardiovascular end points and mortality
in the 10-year follow-up when
compared with conventional treatment
(8,9). Moreover, in the Danish
nationwide study by Schramm et al.
(31), metformin therapy was associated
with lower mortality and cardiovascular
risk when compared with the most
common insulin secretagogues, in line
with new ﬁndings by Hong et al. (10).
These ﬁndings are partially conﬁrmed by
the Dutch randomized, placebo-
controlled trial Hyperinsulinemia: the
Outcome and its Metabolic Effect
(HOME), where metformin treatment
was found to be associated with a lower
Figure 1—Plasma ﬁbulin-1 and blood HbA1c concentrations at baseline and after 1 and 2 years of antidiabetic treatments. The top panel (A) shows
results for plasma ﬁbulin-1 and the bottom panel (B) shows results for HbA1c, both in the four treatment groups as indicated. Data are presented as
mean 6 SEM for the four treatment groups as indicated. *P , 0.01 compared with the control group.
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incidence of macrovascular events (15).
In contrast, the effect of rosiglitazone on
macrovascular events is still
questionable, despite the ability of this
drug type to improve glycemic status
(32–34).
It has previously been reported that
metformin treatment improves
endothelial function (13), and our
ﬁndings are in agreement with one
other human study, where metformin,
in contrast to treatment with
repaglinide, improved markers of
endothelial function, such as von
Willebrand factor, tissue plasminogen
activator, plasminogen activator
inhibitor-1, and intercellular adhesion
molecule despite similar effects on the
glycemic levels (16). Metformin has also
been reported to improve endothelial
function in normoinsulinemic, normal-
weight polycystic ovary syndrome
patients (35), suggesting a possible
direct effect of the drug on arterial cells
beside putative secondary effects due to
the glucose-lowering properties.
Furthermore, several animal studies
show that metformin improves
endothelial function and reduces
remodeling; for example, in a rat model
of induced obesity and insulin
resistance, metformin has been shown
to attenuate hypertrophic vascular
remodeling (36). Likewise, in a rat model
of nonobese T2D, metformin improved
the levels of glycation, vascular
oxidative stress, and nitric oxide
availability and normalized endothelial
function on aorta (37). It was suggested
that metformin, through the activation
of AMP-activated protein kinase,
increases the expression of
mitochondrial uncoupling protein-2,
resulting in the inhibition of both O2 and
prostacyclin synthase nitration in
diabetes (38). Studies indicate that
metformin may exert direct effects on
arterial cells. Thus, metformin appears
to reduce the release of some
proinﬂammatory cytokines through
nuclear factor-kB (39), and, moreover,
in vitro experiments on human aortic
smooth muscle cells demonstrated that
metformin inhibits leptin-induced
nuclear factor-kB activation (40). Our
ﬁndings ﬁt well with the notion that
metformin may exert direct beneﬁcial
effects in the arterial wall and expand
this idea by pointing toward metformin-
induced alterations in the metabolism
of the ECM molecule ﬁbulin-1.
Somewhat surprising, we did not ﬁnd
that rosiglitazone changed plasma
ﬁbulin-1, despite the fact that previous
publications have shown that glitazones
may inﬂuence arterial functions and
change vascular biomarkers (41,42).
Nevertheless, it seems that even though
rosiglitazone may reverse endothelial
dysfunction, it did not change arterial
remodeling in a study of Zucker diabetic
fatty rats (43). Our ﬁndings are
therefore compatible with the notion
that metformin and rosiglitazone
inﬂuence different pathophysiological
pathways in the arterial wall, although
they both improve glycemic status.
In conclusion, we ﬁnd that plasma
ﬁbulin-1 increases over time in patients
with T2D. Importantly, metformin
treatment in T2D leads to a reduction of
this increase, independent of effects on
glycemic status. This is in agreement
with the notion that metformin exerts
direct beneﬁcial effects on arterial cells
and adds effects on the ECM to the
targets of this drug. Rosiglitazone has no
effect on ﬁbulin-1 levels, suggesting that
effects of metformin and glitazones
follow different pathophysiological
pathways in the cardiovascular system.
Our results are compatible with the
hypothesis that ﬁbulin-1 may be an
important molecular marker for
changes in important pathways related
to the development of arterial disease in
T2D.We speculate that measurement of
plasma ﬁbulin-1 levels might have a
potential application as an indicator of
metformin efﬁcacy and a marker of
cardiovascular risk in diabetic patients.
We suggest that further investigations
on the physiology of ﬁbulin-1 may
unravel important mechanisms behind
the development of macrovascular
disease in T2D.
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